Relacorilant Treatment cushing Syndrome: Phase III trial sat trials have been conducted.
-
Last Update: 2020-07-30
-
Source: Internet
-
Author: User
Search more information of high quality chemicals, good prices and reliable suppliers, visit
www.echemi.com
!---- Cushing syndrome is an endocrine disease that is a series of clinical manifestations and signs caused by prolonged exposure to cortisol or excessive secretion.pharmaceutical company Corcept recently announced that it has launched a Phase III clinical trial (GRADIENT study) for relacorilant to treat adrenal cushing syndrome. Dr Andreas Grauer, chief medical officer ofCorcept, said: "Patients with adrenal cushing syndrome are in poor health.We hope that Relacorilant will be a treatment option for these patients."GRADIENT study is a double-blind, placebo-controlled Phase III clinical trial that plans to recruit 130 patients in the United States and Europe.the main endpoint of the trial was to improve glucose metabolism and hypertension.the cause of Cushing syndrome may be a strong pine-like cortisol drug overdose, or it may be because the tumor secretes too much cortisol, or the tumor causes the adrenal gland to produce too much cortisol products, which in turn leads to cushing syndrome.about two to three out of every million people in the country each year suffer from Cushing syndrome.common in people between the ages of 20 and 50.women are three times more likely to develop the disease than men..
This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only.
This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of
the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed
description of the concern or complaint, to
service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content
will be removed immediately.
